Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 08/26/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. CYTK, VKTX, TGTX, KRYS, ACAD, PCVX, AAPG, ACLX, ADMA, and ZLABShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), Arcellx (ACLX), ADMA Biologics (ADMA), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte Ascentage Pharma Group International Arcellx ADMA Biologics Zai Lab Cytokinetics (NASDAQ:CYTK) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations. Do analysts rate CYTK or CALT? Cytokinetics presently has a consensus price target of $71.58, suggesting a potential upside of 89.22%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in CYTK or CALT? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 3.4% of Cytokinetics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings & valuation, CYTK or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Cytokinetics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$18.47M245.09-$589.53M-$5.10-7.42Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Is CYTK or CALT more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Cytokinetics' net margin of -707.17%. Cytokinetics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-707.17% N/A -45.52% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Does the media favor CYTK or CALT? In the previous week, Cytokinetics had 12 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 12 mentions for Cytokinetics and 0 mentions for Calliditas Therapeutics AB (publ). Cytokinetics' average media sentiment score of 1.01 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Cytokinetics is being referred to more favorably in the media. Company Overall Sentiment Cytokinetics Positive Calliditas Therapeutics AB (publ) Neutral Which has more volatility & risk, CYTK or CALT? Cytokinetics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. SummaryCytokinetics beats Calliditas Therapeutics AB (publ) on 10 of the 17 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$853.28M$5.74B$9.78BDividend YieldN/A4.84%4.40%4.04%P/E Ratio-21.621.1630.8326.39Price / Sales0.74138.93382.9086.63Price / CashN/A19.5637.7259.11Price / Book37.746.7710.106.62Net Income-$43.96M-$4.20M$3.26B$265.42M7 Day PerformanceN/A11.77%3.90%3.58%1 Month PerformanceN/A3.47%3.73%0.46%1 Year Performance-1.26%15.88%37.68%19.41% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180CYTKCytokinetics3.6062 of 5 stars$38.95+0.7%$71.58+83.8%-33.1%$4.63B$18.47M-7.64250News CoveragePositive NewsVKTXViking Therapeutics3.9581 of 5 stars$42.09+5.1%$86.92+106.5%-60.3%$4.50BN/A-27.5120TGTXTG Therapeutics4.4113 of 5 stars$27.73-1.2%$46.25+66.8%+18.0%$4.46B$454.07M74.95290Positive NewsKRYSKrystal Biotech4.7176 of 5 stars$146.30-2.6%$210.75+44.1%-26.7%$4.35B$359.21M29.74210ACADACADIA Pharmaceuticals3.253 of 5 stars$25.06-1.1%$28.88+15.2%+59.9%$4.27B$1.02B18.84510Positive NewsPCVXVaxcyte2.3748 of 5 stars$32.09-1.9%$136.50+325.4%-61.9%$4.25BN/A-7.81160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$47.49+5.6%N/AN/A$4.18B$134.35M0.00600Gap DownACLXArcellx2.1025 of 5 stars$71.82-3.1%$114.31+59.2%-2.8%$4.11B$107.94M-21.0080News CoverageADMAADMA Biologics4.3599 of 5 stars$17.63+3.8%$27.67+56.9%-2.1%$4.05B$474.17M20.50530Positive NewsZLABZai Lab2.403 of 5 stars$35.69-0.1%$57.22+60.3%+80.1%$3.97B$398.99M-17.501,869Analyst ForecastGap Down Related Companies and Tools Related Companies Cytokinetics Alternatives Viking Therapeutics Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives Vaxcyte Alternatives Ascentage Pharma Group International Alternatives Arcellx Alternatives ADMA Biologics Alternatives Zai Lab Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access